In short
ZOLPIDEM TARTRATE clinical trials are studying how some people have unusual, or paradoxical, responses to this medicine. The trial data focus on safety and effects in patients with disorders of consciousness, people with acquired vision impairment, and healthy volunteers. The goal is to better understand who responds and what changes are measured in the brain, alertness, and function.
Key points
- ZOLPIDEM TARTRATE clinical trials in the source data are focused on paradoxical responses, meaning unexpected changes seen in some people after treatment. The main study includes patients with disorders of consciousness, people with acquired partial or total vision impairment, and neurotypical volunteers. It is a Phase 2 interventional trial with 180 planned participants. The main outcomes include consciousness level, brain activity, alertness or sleepiness, cognitive performance, and vision function. The trial is currently suspended. Researchers hope the findings will improve understanding of why some people respond differently and may support more personalized care.
Trial overview
This source describes one interventional study, which means the researchers give a study treatment and then measure what happens. The trial title is “Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study.” The study status is Suspended, so it is not currently moving ahead as planned.
Who is being studied
The trial includes three groups: patients with disorders of consciousness (DoC), patients with acquired partial or total vision impairment, and neurotypical volunteers, which means people from the general population used for comparison. The brief summary says the researchers are interested in people who may show a paradoxical response to ZOLPIDEM TARTRATE, meaning an unexpected response rather than the usual one.
In the DoC group, the researchers are looking at whether some participants may recover consciousness after the study intervention. In the vision-impaired group, they are looking at whether some participants may have a temporary return of vision. In neurotypical volunteers, the summary notes possible changes such as trouble falling asleep, higher concentration, and increased agitation in paradoxical responders.
What is being measured
The main outcomes are different for each group, but they all help researchers understand response patterns. For patients with DoC, the study measures consciousness level using the Coma Recovery Scale-Revised (CRS-R), brain complexity using high density electroencephalography (hdEEG), and patient experiences through free recall or interview if functional communication returns.
For neurotypical volunteers, the study measures alertness or sleepiness with the Karolinska Sleepiness Scale (KSS), cognitive performance with standardised neuropsychological tests, brain complexity with hdEEG, and any reported experiences through free recall or interview. For patients with acquired vision impairment, the same alertness, cognitive, brain, and experience measures are used, plus visual function testing by a neuro-ophthalmologist, who is an eye specialist focused on the nervous system and vision.
Study design and phase
The study is listed as Phase 2. Phase 2 studies usually look more closely at whether a treatment has an effect in the target groups and continue to collect information about outcomes. The planned enrollment is 180 participants.
The intervention list includes Zolpidem Viatris 10 mg tablets and mannitol, with administration by oral, nasogastric tube, or percutaneous endoscopic gastrostomy tube use as stated in the source. The source does not provide more detail on dosing schedules beyond this listing.
Why this research matters
The brief summary says the study aims to better understand the mechanisms behind paradoxical responders versus non-paradoxical responders to ZOLPIDEM TARTRATE. This matters because the same treatment may lead to very different results across people, and the researchers want to learn which brain, behavior, or vision changes may help explain those differences. The summary also says the findings could support improved personalised patient care.